When was Proscia founded?

Proscia was founded in 2014 and raised its 1st funding round 2 years after it was founded.

Where is Proscia located?

Proscia is headquartered in Philadelphia, United States. It is registered at Philadelphia · City in Pennsylvania, United States.

How many employees does Proscia have?

As of Jul 31, 2026, the latest employee count at Proscia is 129.

Is Proscia a funded company?

Proscia is a funded company, having raised a total of $129M across 8 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jul 05, 2016.

How much is Proscia worth?

The latest valuation of Proscia is $***** as of Apr 21, 2025.

When was the latest funding round of Proscia?

Proscia's latest funding was a $***** Series C round on Mar 04, 2025, with participation from 9 investors.

Where does Proscia rank among its competitors?

Proscia ranks 13th amongst 314 active competitors, of which 91 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Techcyte, which secured $15M in Apr, 2026.

Who are the top competitors of Proscia?

Proscia's top competitors include PAIGE, PathAI and Ibex. Among them, Techcyte secured the most recent funding round in April, 2026.

Proscia - 2026 Company Profile, Team, Funding & Competitors

Company Details

Proscia’s is a cloud-based software platform that clinic management, analysis, access, and collaboration for slide images in digital pathology. The features of the Proscia platform that allow users to improve whole slide image workflows include secure storage, annotation, and collaboration on digital biopsies. The company has developed a digital pathology platform called Concentriq that uses AI technology for computational pathology applications. The company has developed a tool that assists helathacre providers to diagnose cancer cells using image analysis technology.

Website: proscia.com
Social
Phone Number: +1 **********
Registered Address: Philadelphia · City in Pennsylvania, United States

Key Metrics

Founded Year

2014

Location

Philadelphia, United States

Stage

Series C

Total Funding

$129M in 8 rounds

Latest Funding Round

Series C, Mar 04, 2025, $*****

Post Money Valuation

$***** as on Apr 21, 2025

Investors

Triangle Peak Partners & 23 more

Ranked

13^th among 314 active competitors

Employee Count

129 as on Jul 31, 2026

Similar Companies

PAIGE & 270 more

View Proscia's full profile

Proscia is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Proscia Inc. CIN: 47-1450500 , United States, Active	Jun 30, 2014	-	85 (As on Dec 31, 2022)	-

Proscia has raised a total funding of $129M over 8 rounds. Its first funding round was on Jul 05, 2016. Its latest funding round was a Series C round on Mar 04, 2025 for $*****. 9 investors participated in its latest round. Proscia has 24 institutional investors.

Here is the list of recent funding rounds of Proscia:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 04, 2025	2482570	Series C	2280951	2515067	1031961	5078438
Dec 29, 2023	8637416	Series C	9536467	6838611	3325924	AIC & 2 more
Jun 03, 2022	1539340	Series C	2300360	8355111	1529688	Highline Capital & 7 more

Access funding benchmarks and valuations. Sign up today!

View details of Proscia's funding rounds and investors

The founders of Proscia are Coleman Stavish and David West.

Here are the details of Proscia's key team members:

Coleman Stavish: Co-Founder & CTO of Proscia and founder of 1 other company. They serve on the board of 1 company.
Contact Info: 1 email address
David West: Co-Founder & CEO of Proscia.
Contact Info: 1 email address

Proscia's Board of Directors

Proscia's board has 12 active members. Alexander Niehenke, David West, Coleman Stavish, Jacob Doft, Tom Loftus, Robert Epstein, Stavish Coleman, Charles M. Hazard, David West, Jr., Neil L. Cohen, David West, Sr. and Alex Niehenke are independent board members.

Here is the list of Proscia's board of directors:

Name	Type	Representing	Status	Duration
Alexander Niehenke	Independent board member	-	Current	5y 7m
ylsbpib	Independent board member	-	Current	8y 1m
tucsqtn	Independent board member	-	Current	9y 4m
noaifgf	Independent board member	-	Current	4y 7m
wwcrnmu	Independent board member	-	Current	5y 1m
pwbciev	Independent board member	-	Current	9y 5m
whhiidb	Independent board member	-	Current	2y 3m
hhjtkqb	Independent board member	-	Current	8y 4m
gctshwl	Independent board member	-	Current	2y 5m
pmspoma	Independent board member	-	Current	4y 2m
ltdpydq	Independent board member	-	Current	3y 5m
bcffaax	Independent board member	-	Current	3y 3m

View details of Proscia's Founder profiles and Board Members

Proscia's employee count trend

Proscia has 129 employees as of Jul 26. Here is Proscia's employee count trend over the years:

Uncover Proscia's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Proscia include PAIGE, PathAI and Ibex. Here is the list of Top 10 competitors of Proscia, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	PAIGE 2018, New York City (United States), Acquired	Developer of AI applications and foundation models for cancer diagnostics	$241M	Casdin Capital, Johnson & Johnson Innovation – JJDC ... & 9 others	71/100
2nd	PathAI 2016, Boston (United States), Series C	Provider of digital pathology image management system for clinical labs	$255M	General Catalyst, Merck Global Health Innovation Fund ... & 22 others	71/100
3rd	Ibex 2016, Tel Aviv (Israel), Series C	Provider of AI-powered diagnostic solutions for pathology	$114M	83NORTH, Kreos Capital & 6 others	69/100
4th	Deciphex 2017, Dublin (Ireland), Series C	Network of pathologists providing digital diagnostic services for medical testing	$56.6M	Seroba Life Sciences, Molten Ventures & 13 others	65/100
5th	Aignostics 2018, Berlin (Germany), Series B	Developer of artificial intelligence software for biomedical image analysis applications	$53.9M	Boehringer Ingelheim Venture Fund, Wellington Partners Venture Capital ... & 9 others	64/100
6th	Aiforia 2014, Helsinki (Finland), Public	Provider of an AI and cloud-based, deep learning image analysis platform in all therapy areas	$23M	Ascend Capital Partners, Businessfinland & 8 others	64/100
7th	Techcyte 2014, Orem (United States), Series B	Artificial intelligence (AI) based image analysis platform for pathologists	$50.4M	ARUP Laboratories, Zoetis & 2 others	61/100
8th	Nucle AI 2017, Chicago (United States), Series B	AI-assisted platform for image analysis	$60M	Vertex Ventures Israel, Sanofi Ventures & 9 others	61/100
9th	Onc.ai 2020, San Carlos (United States), Series A	AI-based cancer treatment and diagnosis platform for healthcare providers	$31M	MassMutual, Accomplice & 12 others	61/100
10th	Valar Labs 2021, Palo Alto (United States), Series A	Developer of AI diagnostics for predicting cancer treatment response likelihood	$26.1M	Andreessen Horowitz, DCVC & 18 others	61/100
13th	Proscia 2014, Philadelphia (United States), Series C	Provider of an AI and cloud-based digital pathology solution for cancer diagnosis	$129M	Insight Partners, Venture for America & 22 others	59/100